114 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
Rank Status Study
1 Recruiting Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Conditions: Spontaneous Bacterial Peritonitis;   Ascites;   Liver Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Norfloxacin
2 Recruiting Functional Genomic Influences on Disease Progression and Outcome in Sepsis
Conditions: Pneumonia;   Peritonitis
Intervention:
3 Recruiting Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum
Conditions: Hepatic Dysfunction Transient;   Renal Function Disorder
Interventions: Other: TEAS pretreatment;   Other: TEAS treatment
4 Unknown  Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
Conditions: Portal Hypertension Gastropathy;   Esophageal Varices;   Spontaneous Bacterial Peritonitis;   Hepatic Encephalopathy;   Ascites
Interventions: Drug: propranolol;   Drug: carvedilol;   Drug: placebo
5 Recruiting Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Conditions: Relapsed Epithelial Ovarian Cancer;   Relapsed Primary Peritoneal Cancer;   Relapsed Fallopian Tube Cancer
Interventions: Drug: Birinapant;   Drug: Conatumumab
6 Unknown  Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: liposome-encapsulated doxorubicin citrate;   Procedure: quality-of-life assessment
7 Recruiting Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion
Condition: Peritoneal Neoplasms
Intervention: Behavioral: Questionnaire
8 Unknown  Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: docetaxel;   Drug: idronoxil;   Other: placebo
9 Recruiting An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
Condition: Peritoneal Neoplasms
Intervention:
10 Recruiting Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Conditions: Malignant Neoplasm of Stomach;   Secondary Malignant Neoplasm of Peritoneum;   Secondary Malignant Neoplasm of Other and Unspecified Sites
Intervention: Procedure: HIPEC
11 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: letrozole;   Drug: tamoxifen citrate;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: topotecan hydrochloride;   Drug: trametinib;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
Conditions: Cirrhosis;   Ascites;   Nosocomial Spontaneous Bacterial Peritonitis
Interventions: Drug: Daptomycin + Meropenem;   Drug: Ceftazidime
13 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:
14 Not yet recruiting Adjuvant HIPEC in High Risk Colon Cancer
Conditions: Colorectal Neoplasms;   Peritoneal Neoplasms
Interventions: Procedure: Adjuvant HIPEC (open/laparoscopic);   Drug: Standard adjuvant systemic chemotherapy;   Procedure: Diagnostic laparoscopy
15 Recruiting Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: NK cells;   Biological: IL-2;   Drug: INCB024360
16 Unknown  The Study of Infection and Cell Inflammation in Peritoneal Dialysate
Conditions: Peritonitis;   Kidney Failure
Intervention:
17 Recruiting A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Urinary Bladder Neoplasms;   Carcinoma, Transitional Cell;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Pancreatic Ductal;   Tumor Virus Infections
Interventions: Drug: CC-486 plus Carboplatin;   Drug: CC-486 plus ABI-007;   Drug: CC-486
18 Recruiting Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis
Condition: Perforated Diverticulitis
Interventions: Procedure: Laparoscopic lavage and drainage;   Procedure: Sigmoidectomy with primary anastomosis;   Procedure: Sigmoidectomy with end-colostomy
19 Not yet recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
20 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Triple-negative Breast Cancer
Interventions: Drug: olaparib;   Drug: cediranib maleate;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years